Press Releases TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-03-06 am EST			5-day change	1st Jan Change
0.0706 ^EUR	-3.95%		+2.32%	+8.28%

Jan. 05	TME Pharma N.V. Provides Update on Its Activities	CI
Nov. 17	TME Pharma N.V. Announces Extension of Certain Bond Agreements	CI

Press Releases

Jan. 05	TME Pharma provides update on its activities	GL
Nov. 17	TME Pharma announces receipt of agreements in principle to extend certain bond agreements	GL
Nov. 05	TME Pharma advances its new investment strategy and signs LOI with German resources company	GL
25-10-31	TME Pharma N : 2025, Half-Year Financial Report as of 30 June 2025	PU
25-10-30	TME Pharma publishes its semi annual results and half-year report	GL
25-09-22	TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase	BU
25-09-01	TME Pharma Completes August Financing and Publishes Cash Position	BU
25-08-25	TME Pharma to raise €500k through new bond issue and receives new notice of shareholding	BU
25-07-29	TME Pharma Provides Update About Additional Strategy	BU
25-07-08	TME Pharma: Termination of the Liquidity Contract	BU
25-06-30	TME Pharma Announces New Treasury Investment Policy	BU
25-06-27	TME Pharma Provides Results of Final Exercise of Warrants Z	BU
25-06-25	TME Pharma Appoints Diede van den Ouden as New CEO at the 2025 Annual General Meeting of Shareholders	BU
25-06-18	TME Pharma Announces Successful Next Step in Its NOX-E36 Ophthalmology Strategy With Signature of Option Framework Agreement With Singapore Eye Research Institute (SERI)	BU
25-05-27	TME Pharma Provides Additional Details on the Debt and Warrant Agreements Announced on 21 May That Extend Its Financial Visibility by 12 Months	BU
25-05-26	TME Pharma Announces Convocation of the 2025 Annual General Meeting of Shareholders	BU
25-05-21	TME Pharma N : Inside Information / Other news releases	PU
25-05-21	TME Pharma Extends Its Financial Visibility by 12 Months	BU
25-05-05	TME Pharma Announces That Nominated CEO Plans to Increase His Shareholding	BU
25-05-05	TME Pharma Announces New Strategy	BU
25-04-25	TME Pharma Publishes 2024 Financial Results and Provides Operating Update	BU
25-04-10	TME Pharma Provides Update on Resources Allocated to the Liquidity Contract With Invest Securities	BU
25-03-28	TME Pharma Provides Results of Fifth Exercise of Warrants Z	BU
25-03-13	TME Pharma Announces Filing of Patents for Use of CCL2 Inhibitor NOX-E36 in Ophthalmology and Presentation at ARVO 2025 of Preclinical Data Showing Benefit in Glaucoma Filtration Surgery	BU
25-02-17	TME Pharma CEO Message	BU